RNS Number : 0409D Renalytix AI PLC 24 June 2021 Renalytix AI plc (" Renalytix " or the " Company ") Change of name to Renalytix Plc Change of registered office Change of website NEW YORK , June 24, 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announces it has changed its name to
RNS Number : 7366C Renalytix AI PLC 22 June 2021 The following amendment(s) has been made to the ' Director/PDMR Dealing ' announcement released on 22 June 2021 at 10:57 under RNS No 7062C. The price of 113.5 pence per share was incorrect and has been amended to 1135 pence per share.
RNS Number : 7062C Renalytix AI PLC 22 June 2021 Renalytix AI plc ("Renalytix" or the "Company") Director/PDMR Dealing The Company was informed that today, Christopher Mills , a non-executive director and interim Chairman, completed the sale of 17,000 ordinary shares of 0.25 pence each
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021. Recent Highlights Partnership announced with University of Utah health system to improve
RNS Number : 9139B Renalytix AI PLC 15 June 2021 Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021 NEW YORK , June 15, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) ("Renalytix" or the "Company") today reported financial results for the quarter and nine months
Announces Change of Auditor to Ernst & Young LLP NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced the Company will release fiscal third quarter 2021 financial results on Tuesday, June 15, 2021, before market open.
RNS Number : 4033B Renalytix AI PLC 10 June 2021 Renalytix AI plc (" Renalytix " or the " Company ") Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update Announces Change of Auditor to Ernst & Young LLP NEW YORK , June 10, 2021 - Renalytix AI
Enabling expertise in sales, population health and value-driven care models NEW YORK and SALT LAKE CITY, June 07, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced a series of key hires to drive its commercialization strategy in the United States market in light
RNS Number : 9511A Renalytix AI PLC 07 June 2021 Renalytix AI plc (" Renalytix " or the " Company ") Leadership additions announced to support expanding US Government and Healthcare Provider KidneyIntelX Deployment Enabling expertise in sales, population health and value-driven care models
Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment to improve patient outcomes and reduce healthcare costs NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced results from a new utility study.